Since loss-of-function mutations in TET2 and TP53 are frequently detected in BPDCN patients, we revealed that the over-expression of MYC and RUNX2 initiated the transformation of BPDCN-like disease lacking Tet2 and p53 in mice. The gene discussed is MYC; the disease is CD4+/CD56+ hematodermic neoplasm.